Field Study of innovative therapies in oncology: bevacizumab (Avastin®), an anti-angiogenic agent FRESH-PEF2907-en Cécile DROZ-PERROTEAU Field Study of innovative therapies in oncology: bevacizumab (Avastin®), an anti-angiogenic agent ETNA FRESH-PEF2907-en 2907 FRESH-PEF2907 Annie FOURRIER-REGLAT Nicholas MOORE UNIVERSITE DE BORDEAUX Epidemiology France Portal (PEF) F. HOFFMANN-LA ROCHE AG MINISTERE DU TRAVAIL, DE LA SANTE, DES SOLIDARITES ET DES FAMILLES null Annie;FOURRIER-REGLAT Nicholas;MOORE Metastatic colorectal cancer first-line conditions of use pharmacoepidemiology Department of Pharmacology bevacizumab Avastin® tolerance survival cohort Bordeaux Oncology Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues Healthcare system determinants: Use of care Healthcare system determinants The main objectives of the study were to describe the population of patients with metastatic colorectal cancer and treated in real-life with first-line bevacizumab, describe the conditions of use of this drug, evaluate the safety of treatments and effectiveness in terms of response and overall and progression free survival at 12 and 24 months follow up. null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Patient with metastatic colorectal cancer who initiated bevacizumab in first-line palliative treatment regardless of the associated cancer treatment between 1 January 2006 and 31 December 2007 (whether or not the treatment is continued); Interval between adjuvant chemotherapy for primary cancer and the initiation of bevacizumab ≥6 months; Absence of chemotherapy for metastases before initiation of bevacizumab; Patient had not previously treated with bevacizumab, including during a clinical trial or Temporary Authorisation of Use; Patient with a prescribing physician or their head of department who agreed to participate in the study; Patient not participating in a clinical trial (Huriet-Sérusclat), unless it has a standard treatment (control arm) in an open-label Phase III study (bevacizumab known); Patient not objecting to the data collection. Clinical data Health event/morbidity Health event/mortality Health care consumption and services Other Medical-administrative database (patients health insurance/mutual insurance) Disease and death registry < 500 individuals Converting or copying information into a structured record Observational Study Observational Study 411 Unknown To be defined Ownership of study data was the subject of an agreement between the University of Bordeaux Segalen, the Bordeaux University Hospital and the pharmaceutical company. Access on specific project only